Recently, Hinrichs et al. [37] analyzed the plasma levels of IL-6 in 38 PTLDs undergoing treatment (chemotherapy) for PTLD and demonstrated that pretherapeutic levels of IL-6 were elevated and their levels were correlated with the course of disease; falling in responders and rising in nonresponders. This evidence concerns the gene IL6 and post-transplant lymphoproliferative disease.